上海谊众(688091) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥47,686,380.61, a decrease of 39.46% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥161,171.90, reflecting a significant decline of 99.39% year-over-year[2]. - The basic earnings per share for Q3 2024 was ¥0.00, a decrease of 100.00% compared to the same period last year[2]. - The company experienced a 39.25% decline in operating revenue for the year-to-date period compared to the previous year, primarily due to policy impacts on self-paid chemotherapy drugs[7]. - The net profit attributable to shareholders for the year-to-date period decreased by 73.46% year-over-year[8]. - Total operating revenue for the first three quarters of 2024 was ¥169,608,230.26, a decrease of 39.2% compared to ¥279,201,375.63 in the same period of 2023[21]. - Net profit for the first three quarters of 2024 was ¥34,670,092.06, down 73.5% from ¥130,623,890.97 in the same period of 2023[24]. - The total comprehensive income for the third quarter of 2024 was CNY 34,670,092.06, compared to CNY 130,623,890.97 in the same period of 2023, indicating a significant decrease[25]. Research and Development - The R&D investment totaled ¥10,014,224.87 in Q3 2024, an increase of 29.68% compared to the same period last year, representing 21.00% of operating revenue[4]. - Research and development expenses rose to ¥25,344,606.05, compared to ¥16,707,263.59 in the previous year, marking an increase of 51.8%[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,488,082,087.73, down 5.42% from the end of the previous year[4]. - The company's current assets decreased to RMB 845,817,088.99 from RMB 1,413,243,663.87 as of December 31, 2023, reflecting a significant reduction[17]. - Total assets decreased to ¥1,488,082,087.73 from ¥1,573,359,475.20, a decline of 5.4%[20]. - Total liabilities decreased to ¥50,898,376.90 from ¥108,522,872.33, a reduction of 53.1%[20]. - Shareholders' equity totaled ¥1,437,183,710.83, down from ¥1,464,836,602.87, a decrease of 1.9%[20]. - The company’s total liabilities to total assets ratio improved to 3.4% from 6.9%[20]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥20,865,363.56, a decrease of 66.74% year-over-year[2]. - Cash inflow from operating activities for the first three quarters of 2024 was CNY 201,750,223.36, slightly up from CNY 199,731,444.67 in the same period of 2023[26]. - Net cash flow from operating activities for the first three quarters of 2024 was CNY 20,865,363.56, down from CNY 62,726,942.85 in the same period of 2023[26]. - Cash inflow from investment activities for the first three quarters of 2024 was CNY 2,911,837,099.66, compared to CNY 1,069,893,593.22 in the same period of 2023, showing a substantial increase[26]. - Net cash flow from investment activities for the first three quarters of 2024 was -CNY 168,798,149.82, a decrease from CNY 53,719,564.68 in the same period of 2023[26]. - Net cash flow from financing activities for the third quarter of 2024 was -CNY 110,822,617.12, compared to -CNY 23,281,275.34 in the same period of 2023[27]. - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 was CNY 651,130,264.21, down from CNY 799,411,738.71 at the end of the same period in 2023[27]. - The company reported a cash outflow of CNY 109,311,207.02 related to other operating activities in the first three quarters of 2024, compared to CNY 65,889,938.78 in the same period of 2023[26]. - The company experienced a significant increase in cash outflow for investment activities, totaling CNY 3,080,635,249.48 in the first three quarters of 2024, compared to CNY 1,016,174,028.54 in the same period of 2023[26]. Shareholder Information - The company reported a total of 10,000 ordinary shareholders at the end of the reporting period[9]. - Major shareholders include Zhou Jinsong with a 19.50% stake and Shanghai Kaibao Pharmaceutical Co., Ltd. with a 12.01% stake[9]. - As of September 30, 2024, the company repurchased a total of 1,065,694 shares, accounting for 0.5179% of the total share capital of 205,759,840 shares, with a total expenditure of RMB 27,935,885.49[14]. Strategic Focus - The company is focused on enhancing its market position through strategic investments and operational efficiencies[18]. - The company reported a significant increase in sales expenses to ¥83,790,558.19 from ¥78,776,674.20, an increase of 6.4%[24]. - The company recorded an investment income of ¥7,371,746.28, compared to ¥4,953,402.72 in the previous year, an increase of 48.7%[24]. - The company has ongoing investments in construction projects, with a value of RMB 24,314,161.70, up from RMB 4,806,580.51[17]. - The company holds other non-current assets valued at RMB 486,946,450.70, significantly higher than RMB 23,819,084.19 previously[17]. - The company’s total liabilities and equity structure will be closely monitored as part of future financial strategies[18].